1. Rovira À, Auger C, Sceppacuercia S, Torres C. Typical and emerging diagnostic MRI features in multiple sclerosis.
Can Assoc Radiol J 2025;76:122-144.
2. Gill AJ, Schorr EM, Gadani SP, Calabresi PA. Emerging imaging and liquid biomarkers in multiple sclerosis.
Eur J Immunol 2023;53:e2250228.
3. Sahraian MA, Eshaghi A. Role of MRI in diagnosis and treatment of multiple sclerosis.
Clin Neurol Neurosurg 2010;112:609-615.
4. Dawson JW. The histology of disseminated sclerosis.
Trans R Soc Edinb 1916;45:517-740.
5. Meaton I, Altokhis A, Allen CM, Clarke MA, Sinnecker T, Meier D, et al. Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Mult Scler 2022;28:2212-2220.
6. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.
Ann Neurol 2001;50:121-127.
7. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”.
Ann Neurol 2005;58:840-846.
8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Ann Neurol 2011;69:292-302.
9. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Lancet Neurol 2016;15:292-303.
10. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol 2018;17:162-173.
11. Borrelli S, Martire MS, Stölting A, Bulcke CV, Pedrini E, Guisset F, et al. Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm 2024;11:e200253.
12. Rocca MA, Preziosa P, Barkhof F, Brownlee W, Calabrese M, Stefano ND, et al. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis.
Lancet Reg Health Eur 2024;44:100978.
13. Montalban X. Revised McDonald criteria 2023. In: The 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. ECTRIMS, 2024.
14. Balasa R, Barcutean L, Mosora O, Manu D. Reviewing the significance of blood-brain barrier disruption in multiple sclerosis pathology and treatment.
Int J Mol Sci 2021;22:8370.
15. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Association of chronic active multiple sclerosis lesions with disability in vivo.
JAMA Neurol 2019;76:1474-1483.
16. Adams CW, Poston RN, Buk SJ, Sidh YS, Vipond H. Inflammatory vasculitis in multiple sclerosis.
J Neurol Sci 1985;69:269-283.
17. Kolb H, Al-Louzi O, Beck ES, Sati P, Absinta M, Reich DS. From pathology to MRI and back: clinically relevant biomarkers of multiple sclerosis lesions.
Neuroimage Clin 2022;36:103194.
18. Casini G, Yurashevich M, Vanga R, Dash S, Dhib-Jalbut S, Gerhardstein B, et al. Are periventricular lesions specific for multiple sclerosis.
J Neurol Neurophysiol 2013;4:150.
19. López-Gómez J, Enciso BS, Miró MAC, Pascual MRQ. Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis.
Neurologia 2023;38:663-670.
20. Lebrun-Frenay C, Kantarci O, Siva A, Azevedo CJ, Makhani N, Pelletier D, et al. Radiologically isolated syndrome.
Lancet Neurol 2023;22:1075-1086.
21. Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
Nat Rev Neurol 2016;12:714-722.
22. Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, et al. Central vein sign: a diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multi center trial.
Neuroimage Clin 2021;32:102834.
23. Tallantyre EC, Dixon JE, Donaldson I, Owens T, Morgan PS, Morris PG, et al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions.
Neurology 2011;76:534-539.
24. Solomon AJ, Watts R, Ontaneda D, Absinta M, Sati P, Reich DS. Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
Mult Scler 2018;24:750-757.
25. Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.
JAMA Neurol 2019;76:1446-1456.
26. Reeves JA, Bartnik A, Jakimovski D, Mohebbi M, Bergsland N, Salman F, et al. Associations between paramagnetic rim lesion evolution and clinical and radiologic disease progression in persons with multiple sclerosis.
Neurology 2024;103:e210004.
27. Calvi A, Clarke MA, Prados F, Chard D, Ciccarelli O, Alberich M, et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
Mult Scler 2022;29:352-362.
28. Klistorner S, Usnich T, Clarke MA, Pareto D, Rovira À, Paul F, et al. The presence of a paramagnetic phase rim is linked to lesion age in multiple sclerosis.
medRxiv 2025 Jan 13. [Epub ahead of print].
29. Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Brain 2019;142:133-145.
30. Maggi P, Sati P, Nair G, Cortese ICM, Jacobson S, Smith BR, et al. Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study.
Ann Neurol 2020;88:1034-1042.
31. Kwong KCNK, Mollison D, Meijboom R, York EN, Kampaite A, Thrippleton MJ, et al. The prevalence of paramagnetic rim lesions in multiple sclerosis: a systematic review and meta-analysis.
PLoS One 2021;16:e0256845.
32. Elliott C, Rudko DA, Arnold DL, Fetco D, Elkady AM, Araújo D, et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
Mult Scler 2023;29:680-690.
33. Sethi V, Muhlert N, Ron M, Golay X, Wheeler-Kingshott CA, Miller DH, et al. MS cortical lesions on DIR: not quite what they seem?
PLoS One 2013;8:e78879.
34. Mainero C, Treaba CA, Barbuti E. Imaging cortical lesions in multiple sclerosis.
Curr Opin Neurol 2023;36:222-228.
35. Calabrese M. Filippi M, Gallo P. Cortical lesions in multiple sclerosis.
Nat Rev Neurol 2010;6:438-444.
36. Bouman PM, Noteboom S, Santos FA, Beck ES, Bliault G, Castellaro M. Multicenter evaluation of AI-generated DIR and PSIR for cortical and juxtacortical multiple sclerosis lesion detection.
Radiology 2023;307:e221425.
37. Madsen MAJ, Wiggermann V, Bramow S, Christensen JR, Sellebjerg F, Siebner HR. Imaging cortical multiple sclerosis lesions with ultrahigh field MRI.
Neuroimage Clin 2021;32:102847.
38. Nabizadeh F, Masrouri S, Ramezannezhad E, Ghaderi A, Sharafi AM, Soraneh S, et al. Artificial intelligence in the diagnosis of multiple sclerosis: a systematic review.
Mult Scler Relat Disord 2022;59:103673.
39. Krijnen EA, van Dam M, Bajrami A, Bouman PM, Noteboom S, Barkhof F, et al. Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.
Ann Clin Transl Neurol 2025;12:121-136.
40. Ziccardi S, Pisani AI, Schiavi GM, Guandalini M, Crescenzo F, Colombi A, et al. Cortical lesions at diagnosis predict long-term cognitive impairment in multiple sclerosis: a 20-year study.
Eur J Neurol 2023;30:1378-1388.